Ϫ CD27 Ϫ Vg9Vd2 T cell effectors, and a significant unresponsiveness, measured as antigen-driven interferon-g production, was observed during STI. After HAART resumption and consequent inhibition of HIV replication, Vg9Vd2 T cell reactivity was restored both quantitatively and functionally. These observations indicate that Vg9Vd2 T cells are activated early after active HIV replication but are rapidly lost when viremia is not controlled.
T cells expressing Vg9Vd2 display lytic and proliferative responses against human immunodeficiency virus (HIV)-infected cells and release antiviral soluble factors. Chronic HIVpositive patients have deep changes in the composition and function of the circulating gd T cell pool that are restored by highly active antiretroviral therapy (HAART). gd T cells were analyzed during the rapid plasma HIV RNA rebound in HIV-infected patients undergoing structured treatment interruption (STI). A loss in circulating Vg9Vd2 T cells was observed, indicating that acute HIV replication may influence Vg9Vd2 homeostasis. These cells were lost among CD45RA
Ϫ CD27 Ϫ Vg9Vd2 T cell effectors, and a significant unresponsiveness, measured as antigen-driven interferon-g production, was observed during STI. After HAART resumption and consequent inhibition of HIV replication, Vg9Vd2 T cell reactivity was restored both quantitatively and functionally. These observations indicate that Vg9Vd2 T cells are activated early after active HIV replication but are rapidly lost when viremia is not controlled.
gd T lymphocytes recognize nonpeptide microbial antigens without antigen processing by professional antigen-presenting cells (reviewed in [1] ). Among humans, an apparent homogeneity of circulating gd T cells is observed; these cells mainly express a paired Vg9-Vd2 (Vg2-Vd2 in alternate nomenclature) T cell receptor (TCR) [2] . Vg9Vd2 T cells are broadly reactive against various intracellular pathogens and in vitro display both proliferative and lytic responses to human immunodeficiency virus (HIV)-infected cells [1] . Similar to NK cells, a large fraction of circulating Vg9Vd2 T lymphocytes express major histocompatibility complex class I receptors, mostly the inhibitory CD94/ NKG2 complex [1] . Triggering of CD94/NKG2A down-modulates activation of the gd TCR by nonpeptide microbial antigens, interfering with the TCR signaling cascade and controlling the cytolytic activity of peripheral blood Vg9Vd2 T cells and Vg9Vd2 T cell clones against HIV-infected cells [3] . Moreover, activated Vg9Vd2 T cells can suppress in vitro HIV replication by releasing soluble factors, including b-chemokines [4] .
Effector/memory T cells can be distinguished according to the expression of CD45RA and CD27 molecules: central memory cells are CD45RA Ϫ CD27 ϩ , whereas effector memory cells have lost the expression of CD27 costimulatory molecules and lack the proliferative potential of central memory cells. We recently showed that effector memory gd T cells have lost CD27 expression and are lacking in immunocompromised hosts [5] . Alterations of gd T cell distribution were reported elsewhere in the peripheral blood of HIV-infected subjects, including a decrease in both absolute number and function of Vg9Vd2 T cells [6] . We showed elsewhere a marked decrease in the functional reactivity of gd T lymphocytes from HIV-infected persons with opportunistic infections and coinfections. Moreover, highly active antiretroviral therapy (HAART) was able to restore Vg9Vd2 T cell number and reactivity [7] .
Strong HIV-specific immune responses are detected in subjects who intermittently adhere to HAART regimens [8] , suggesting that structured treatment interruption (STI) may be used as a therapeutic strategy to boost HIV-specific immunity. However, such a strategy could be associated with the risk of HIV-mediated loss of CD4 ϩ T cells, severe constitutional symptoms such as those in primary infection, and the emergence of viral mutations conferring drug resistance [9] . Thus, identification of the immunologic and virologic consequences of STI in HIV-infected patients is crucial for the clinical development of novel long-term treatment strategies.
Patients and Methods
Patient recruitment. In this study, we examined the properties of gd T lymphocytes in HIV-infected persons who showed a rapid plasma virus rebound after STI. Ten asymptomatic chronically HIV-1-infected patients were recruited from the National Institute for Infectious Diseases "Lazzaro Spallanzani," Rome. The criteria for study inclusion were у2 years of successful HAART, stable CD4 ϩ T cell counts 1500 cells/mL for у12 months before study entry, undetectable HIV RNA plasma levels (!50 copies/mL by branched DNA assay [bDNA version 3.0; Bayer Diagnostics]) for у12 months before entry, and HAART discontinuation for side effects or spontaneous request. The patients underwent a singlecycle STI consisting of у1 month of discontinuation. HAART reintroduction was decided upon according to current guidelines on antiretroviral therapy (CD4 T cell count !350 cells/mL and/or HIV RNA level 130,000 copies/mL; at http://www.hivatis.org/ trtgdlns.html). In the study patients, a rapid plasma HIV RNA rebound of 130,000 copies/mL was observed after days. 28.7 ‫ע‬ 1.8 Clinical and immunologic follow-up was done when HAART was suspended (T0), 1 month after suspension (T1), at resumption of HAART (T2: days), and 30 days after HAART re-42.3 ‫ע‬ 7.1 sumption (T3).
Monoclonal antibodies and flow cytometric analysis. At each time point, circulating CD4, CD8, and Vd2 T cell counts were determined by flow cytometry by using anti-CD4 ϩ (IgG1, clone 13B8.2), anti-CD8 ϩ (IgG1, clone B9.11), anti-T cell receptor-Vd2 (IgG1, clone IMMU389), and anti-CD3 (IgG1, clone UCHT1) directly coupled to fluorochromes (fluorescein isothiocyanate/phycoerythrin [PE]; purchased from Immunotech). Naive/effector/ memory composition [10] was assessed by anti-CD45RA (IgG2b, clone HI100) and anti-CD27 (IgG1, clone M-T271) directly coupled to fluorochromes (PE-cyanin 5.1, allophycocyanin; purchased from Becton Dickinson Biosciences). Isotype-matched controls from Becton Dickinson Biosciences were used in all experiments. For each sample, 30,000 lymphocyte events were acquired by a FACS-Calibur instrument and analyzed by CellQuest software (Becton Dickinson Immunocytometry Systems).
In Figure 1A shows the Vg9Vd2 T cell counts evaluated at the same time points as in table 1. There was a nonsignificant mean increase in Vd2 T cells at T1 (after 1 month of STI) that was followed by a significant decrease at the end of STI (T2), just before HAART resumption ( , T2 vs. T1). At T3, after P ! .05 1 month of HAART, Vd2 T cells recovered to the level before figure 1A) . Figure 1B shows the effector phenotype of circulating Vd2 T cells. At the end of STI (T2), a significant decrease of CD45RA Ϫ CD27 Ϫ effector cells among Vd2 cells was observed ( , T2 vs. T0). P ! .05 As shown elsewhere [5] , a significant decrease in the percentage of CD45RA Ϫ CD27 Ϫ Vd2 effector cells was found at all time points, compared with those in HIV-negative control subjects (data not shown). Of interest, the ratio of Vd2 effector cells recovered to the pre-STI level among all Vd2 T cells after 1 month of HAART ( figure 1B) . Figure 1C shows the changes in Vd2 T cell function during STI, measured as IPP-induced IFN-g release (related to 10 3 Vd2 cells). A deep decrease in IFN-g release was found soon after treatment interruption at T1 ( , T1 vs. T0; figure 1C ), which lasted to T2 ( P ! .05 P ! , T2 vs. T0; figure 1C ). The HAART-induced recovery in .05 Vd2 T cell number and composition also produced fully competent (i.e., IFN-g-releasing) Vd2 T cells ( , T3 vs. T0; P 1 .05 figure 1C ).
Discussion
The identification of immunologic changes during STI is crucial for assessing its clinical value. In this study, we analyzed the influence of plasma HIV RNA rebound induced by STI on Vg9Vd2 T cell number and function. As expected, a drop in CD4 T cell count and an increase in CD8 T cell count accompanied the rebound in plasma HIV RNA levels. During STI, a reduction of Vg9Vd2 T cell effectors was preceded and accompanied by a functional anergy. Because HAART resumption and virus level reduction were associated with a quantitative and functional restoration of Vg9Vd2 T cells, our observations indicate that this cell subset is deeply affected by the acute response to HIV replication.
The changes in Vg9Vd2 T cells described indicate a specific alteration of these cells in chronically HIV-infected persons [6] . Because most Vg9Vd2 T cells are CD4
Ϫ and resistant to HIV infection, their impairment must result from an indirect mechanism triggered by HIV replication. The gd T cell anergy could be induced by HIV-infected cells through the triggering of the CD94/NKG2-A inhibitory receptors [3] or by negative clonal selection of Vg9Vd2 T cells reactive to nonpeptidic microbial phosphoantigens released by cytopathic effects following HIV infection [1] . In this context, the Vg9Vd2 T cell loss observed after the STI-induced increase of plasma HIV RNA could reproduce the scenario during the very early phases of HIV infection.
Our data indicate that soon after plasma HIV RNA rebound, these cells first become rapidly anergic and then undergo a profound depletion. Indeed, the cytopathic effect of HIV infection may force Vg9Vd2 T cells to enter into an unresponsive or anergic state through stimulation by cell-released phosphoantigens [13] . Furthermore, chronic HIV infection causes selective activation of Vg9Vd2 T cells, resulting in the loss by exhaustion of differentiated CD45RA Ϫ
CD27
Ϫ Vg9Vd2 effector T cells [5] . These observations suggest that Vg9Vd2 T cell alterations during HIV replication could be induced by massive exposure to antigen stimulation and consequent activation-induced cell death of phosphoantigen-reactive Vg9Vd2 T cell effectors [14] .
Vg9Vd2 T cells suppress HIV replication in vitro by soluble factors that include b-chemokines [4] . Moreover, activated Vg9Vd2 T cells produce significant amounts of IFN-g, which in turn may be important to promote the antiviral immune response. Thus, their loss may represent severe indirect damage that reduces both the effectiveness of cell-mediated immune response and the level of antiviral b-chemokines. In the early phases of HIV disease, this may contribute to the establishment of a persistent infection [4] . Increased morbidity and mortality was recently observed in HIV-infected patients who interrupted antiretroviral treatment because of severe side effects [15] . The rapid HIV-induced functional and numeric loss of Vg9Vd2 T cells, although rapidly restored by HAART, may contribute to increased risk of opportunistic infections. This underscores the importance of careful application of STI.
